Across TCGA pan-cancer cohorts, SPRTN Mutation is linked to patient survival in 4 of 34 cancer types, making it a survival-associated SPRTN data layer compared with 22 for mass-spec protein and 2 for mass-spec protein.
The strongest signal is observed in colon adenocarcinoma (COAD), where higher SPRTN Mutation is associated with worse overall survival. In most high-consensus cancer types, elevated SPRTN expression acts as an unfavorable survival marker.
COAD, LIHC, and LUSC are the cancer types where SPRTN Mutation most reproducibly stratifies survival.
Mutation survival associations by lineage
Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.